These authors contributed equally to this work
Disequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravis
Version of Record online: 23 MAR 2009
© 2009 Blackwell Publishing Ltd
Volume 128, Issue 1pt2, pages e826–e836, September 2009
How to Cite
Mu, L., Sun, B., Kong, Q., Wang, J., Wang, G., Zhang, S., Wang, D., Liu, Y., Liu, Y., An, H. and Li, H. (2009), Disequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravis. Immunology, 128: e826–e836. doi: 10.1111/j.1365-2567.2009.03089.x
- Issue online: 4 AUG 2009
- Version of Record online: 23 MAR 2009
- Received 11 December 2008; revised 5 February 2009; accepted 16 February 2009.
- 1Multiple sclerosis: a battle between destruction and repair. J Neurochem 2007; 100:295–306., .
- 2Immunosteroid as a regulator for Th1/Th2 balance: its possible role in autoimmune diseases. Autoimmunity 2005; 38:369–75., , , , .
- 3Supplementation of CD4+CD25+ regulatory T cells suppresses experimental autoimmune uveoretinitis. Br J Ophthalmol 2007; 91:105–10., , , , , , , .
- 4Production of interleukin (IL)-5 and IL-10 accompanies T helper cell type 1 (Th1) cytokine responses to a major thyroid self-antigen, thyroglobulin, in health and autoimmune thyroid disease. Clin Exp Immunol 2007; 147:287–95., , , , , .
- 5Th1 and Th2 lymphocytes in autoimmune disease. Crit Rev Immunol 2005; 25:75–102., .
- 6Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441:235–8., , , , , , , .
- 7Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006; 441:231–4., , et al.
- 8Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006; 24:677–88., , , , .
- 9Role of IL-17 and regulatory T lymphocytes in a systemic autoimmune disease. J Exp Med 2006; 203:2785–91., , , , .
- 10IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 2006; 177:566–73., , , , , , , .
- 11CNS myeloid DCs presenting endogenous myelin peptides ‘preferentially’ polarize CD4+ T(H)-17 cells in relapsing EAE. Nat Immunol 2007; 8:172–80., , , .
- 12Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003; 421:744–8., , et al.
- 13IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201:233–40., , et al.
- 14Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003; 198:1951–7., , , , , , , .
- 15Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999; 42:963–70., , , , , , .
- 16Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 2000; 9:589–93., , , .
- 17Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors. J Immunol 1999; 162:577–84., , , , , , .
- 18Increased urinary excretion of interleukin-17 in nephrotic patients. Nephron 2002; 91:243–9., .
- 19Proinflammatory cytokines (IL-17, IL-6, IL-18 and IL-12) and Th cytokines (IFN-gamma, IL-4, IL-10 and IL-13) in patients with allergic asthma. Clin Exp Immunol 2001; 125:177–83., , , , , , .
- 20Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002; 8:500–8., , et al.
- 21Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 2002; 17:375–87., , et al.
- 22Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003; 171:6173–7., , , .
- 23IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci USA 2003; 100:5986–90., , , , , .
- 24Acetylcholinesterase inhibitors and cholinergic modulation in myasthenia gravis and neuroinflammation. J Neuroimmunol 2008; 202:121–7., , , , .
- 25Animal models of myasthenia gravis. Clin Immunol 2000; 94:75–87., , .
- 26C57BL/6 mice genetically deficient in IL-12/IL-23 and IFN-gamma are susceptible to experimental autoimmune myasthenia gravis, suggesting a pathogenic role of non-Th1 cells. J Immunol 2007; 178:7072–80., , , , , , .
- 27Breakdown of tolerance to a self-peptide of acetylcholine receptor alpha-subunit induces experimental myasthenia gravis in rats. J Immunol 2004; 172:2697–703., , et al.
- 28Macrophage apoptosis in muscle tissue in experimental autoimmune myasthenia gravis. Muscle Nerve 1998; 21:1071–4., , , .
- 29Th1 and Th2 CD4+ T cells provide help for B cell clonal expansion and antibody synthesis in a similar manner in vivo. J Immunol 2000; 165:3136–44., , , , , , , .
- 30Role for interferon-gamma in rat strains with different susceptibility to experimental autoimmune myasthenia gravis. Clin Immunol 2000; 95:156–62., , , , , .
- 31Myasthenia gravis-like syndrome induced by expression of interferon gamma in the neuromuscular junction. J Exp Med 1995; 181:547–57., , et al.
- 32Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice. J Exp Med 1997; 186:385–91., , , , , , .
- 33The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis. J Immunol 1998; 161:2856–62., , , , .
- 34CD4+ T and B cells cooperate in the immunoregulation of experimental autoimmune myasthenia gravis. J Neuroimmunol 2006; 179:152–62., , , , .
- 35T cells and cytokines in the pathogenesis of acquired myasthenia gravis. Ann N Y Acad Sci 2003; 998:284–7., , , .
- 36Experimental autoimmune myasthenia gravis may occur in the context of a polarized Th1- or Th2-type immune response in rats. J Immunol 1999; 162:7189–97., , , , , , , .
- 37Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in the prevention of autoimmune myasthenia. J Immunol 2005; 175:7898–904., , et al.
- 38Ex vivo generated regulatory T cells modulate experimental autoimmune myasthenia gravis. J Immunol 2008; 180:2132–9., , , .
- 39Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Curr Opin Immunol 2006; 18:349–56., , .
- 40Immunization of mice with T cell-dependent antigens promotes IL-6 and TNF-alpha production in muscle cells. Cytokine 2006; 35:100–6., , , , .
- 41A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 2007; 13:139–45..
- 42Low-dose peptide tolerance therapy of lupus generates plasmacytoid dendritic cells that cause expansion of autoantigen-specific regulatory T cells and contraction of inflammatory Th17 cells. J Immunol 2007; 178:7849–58., , .
- 43IL-17 and the Th17 lineage in systemic lupus erythematosus. Curr Opin Rheumatol 2008; 20:519–25., , .
- 44Interleukin-17 family members and inflammation. Immunity 2004; 21:467–76., .
- 45Emerging cytokine targets in rheumatoid arthritis. Curr Opin Rheumatol 2007; 19:246–51., .
- 46Stimulation of airway mucin gene expression by interleukin (IL)-17 through IL-6 paracrine/autocrine loop. J Biol Chem 2003; 278:17036–43., , , , , .
- 47Anti-type V collagen lymphocytes that express IL-17 and IL-23 induce rejection pathology in fresh and well-healed lung transplants. Am J Transplant 2006; 6:724–35., , et al.
- 48Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol 2008; 9:166–75., , et al.